Nucala 100 MG/ML auto-injectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FJFT1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,932
Award facts
- Contract value 100% obligated
- $1,931.83 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order valued at $1,931.83 to DMS Pharmaceutical Group Inc. for Nucala 100 mg/mL auto-injector units, with an ultimate completion date of January 13, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded this delivery order without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The place of performance is located in Park Ridge, Illinois, and the contract represents one of numerous delivery orders issued to this vendor under its broader pharmaceutical supply relationship with the Defense Logistics Agency.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support Department of Defense healthcare operations globally. The underlying IDC, designated SPE2DR and valued at $499,999,999, was awarded on November 13, 2025, and positions DMS Pharmaceutical Group as a critical regional prime vendor contractor authorized to supply a comprehensive range of pharmaceutical products, biologics, and medical consumables to military healthcare facilities worldwide through firm fixed-price delivery orders. The company's established performance across diverse product categories and therapeutic areas demonstrates its capability to fulfill specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FJFT1?
SPE2DR26FJFT1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26FJFT1 worth?
The government has obligated $1,932 on SPE2DR26FJFT1.
Is contract SPE2DR26FJFT1 an order under another contract?
Yes. SPE2DR26FJFT1 is a delivery order under SPE2DR25D9157, an indefinite delivery contract.
Was contract SPE2DR26FJFT1 competed?
The extent of competition for SPE2DR26FJFT1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award